Skip Nav Destination
Issues
1 January 1999
ISSN 1078-0432
EISSN 1557-3265
Editorial
Advances in Brief
Treatment with Farnesyl-Protein Transferase Inhibitor Induces Regression of Mammary Tumors in Transforming Growth Factor (TGF) α and TGFα/neu Transgenic Mice by Inhibition of Mitogenic Activity and Induction of Apoptosis1
Peter Nørgaard; Brian Law; Heather Joseph; David L. Page; Yu Shyr; Debbie Mays; Jennifer A. Pietenpol; Nancy E. Kohl; Allen Oliff; Robert J. Coffey, Jr.; Hans Skovgaard Poulsen; Harold L. Moses
Clinical Trials
A Comparison of Clinical Pharmacodynamics of Different Administration Schedules of Oral Topotecan (Hycamtin)
Cees J. H. Gerrits; Jan H. M. Schellens; Howard Burris; John R. Eckardt; Andre S. T. Planting; Maria E. L. van der Burg; Gail I. Rodriguez; Walter J. Loos; Vera van Beurden; Ian Hudson; Daniel D. Von Hoff; Jaap Verweij
Phase I Clinical and Pharmacokinetic Study of PK1 [N-(2-Hydroxypropyl)methacrylamide Copolymer Doxorubicin]: First Member of a New Class of Chemotherapeutic Agents—Drug-Polymer Conjugates1
Paul A. Vasey; Stan B. Kaye; Rosemary Morrison; Chris Twelves; Peter Wilson; Ruth Duncan; Alison H. Thomson; Lilian S. Murray; Tom E. Hilditch; Tom Murray; Sally Burtles; D. Fraier; E. Frigerio; Jim Cassidy; on behalf of the Cancer Research Campaign Phase I/II Committee
Hepatic Transcatheter Arterial Chemoembolization Alternating with Systemic Protracted Continuous Infusion 5-Fluorouracil for Gastrointestinal Malignancies Metastatic to Liver: A Phase II Trial of the Puget Sound Oncology Consortium (PSOC 1104)1
Linda M. Bavisotto; Nilesh H. Patel; Sandra J. Althaus; Douglas M. Coldwell; Hanh V. Nghiem; Tove Thompson; Barry Storer; Charles R. Thomas, Jr.
Molecular Oncology, Markers, Clinical Correlates
Thrombospondins I and II Messenger RNA Expression in Lung Carcinoma: Relationship with p53 Alterations, Angiogenic Growth Factors, and Vascular Density1
Gabriella Fontanini; Laura Boldrini; Alessandra Calcinai; Silvana Chinè; Marco Lucchi; Alfredo Mussi; Carlo Alberto Angeletti; Fulvio Basolo; Generoso Bevilacqua
Experimental Therapeutics, Preclinical Pharmacology
Attenuation of WAF1/Cip1 Expression by an Antisense Adenovirus Expression Vector Sensitizes Glioblastoma Cells to Apoptosis Induced by Chemotherapeutic Agents 1,3-Bis(2-chloroethyl)-1-nitrosourea and Cisplatin1
Sanbao Ruan; M. Fatih Okcu; Rey-Chen Pong; Michael Andreeff; Victor Levin; Jer-Tsong Hsieh; Wei Zhang
Errata
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.